ClinicalTrials.gg
CompletedNCT06427096Updated Mar 4, 2026

Effect of Healthy Family Program on Population Blood Pressure

An interventional study of Multifaceted intervention in Blood Pressure and Public Health, sponsored by Heart Health Research Center. Completed at 1 site in China. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Heart Health Research Center · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8,001
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

This is a 1:1 parallel design, multi-center, cluster-randomized control trial. A total of 80 villages in Ruyang County, Henan Province, China, will be randomly assigned to the intervention group or control group. At least 100 participants from 30-50 families in each village will be included in this study. The intervention group will engage in a variety of strategies, including educating a healthy lifestyle, adopting a low-sodium diet, managing weight, participating in physical exercise, monitoring blood pressure, and undergoing antihypertensive treatment. These efforts will be led by family health instructors from the community. The control group will receive usual care. The primary endpoint of this study is the change of systolic blood pressure from baseline to 6 months, reported as the difference between intervention and control group.

Read the detailed description

This cluster-randomized control trial aims to randomly allocate 80 villages in Ruyan County to either receive a multifaceted intervention led by family health instructors or continue with usual care. Each village will recruit around 100 individuals aged 40-80 years, with or without hypertension. In intervention villages, a blood pressure management team, headed by family health instructors and family leaders, will implement various strategies including promoting a low-sodium diet, weight management, physical exercise, blood pressure monitoring, and administering antihypertensive treatment. The intervention will span 6 months, followed by another 6-month follow-up period. The primary hypothesis posits that the mean systolic blood pressure change from baseline to 6 months will be higher in the intervention group compared to the control group. The objective of this "Health Family Program" is to evaluate the efficacy of a non-healthcare provider-led multifaceted intervention in enhancing healthy lifestyles and managing blood pressure among rural residents, regardless of their hypertension status, in China.

02

Conditions studied

  • Blood Pressure
  • Public Health

Keywords

  • cluster randomized trial
  • blood pressure
  • family intervention
  • China
03

In context

Lead sponsor

Heart Health Research Center is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  1. Village screening:

    Villages were eligible for inclusion if they had ≥200 permanent households, with ≥60 households comprising ≥2 family members.

  2. Inclusion and Exclusion Criteria for the Family

Inclusion Criteria:

  1. At least 2 participants between the age of 40-80 years meet the inclusion and exclusion criteria of family members and willing to participate in this study;
  2. At least one family member can use the smartphone to upload BP values.

Exclusion Criteria:

  1. Any family member participated in the other hypertension-related programs;
  2. Inappropriate for the study decided by the healthy family instructor.

3.Inclusion and Exclusion Criteria for the Family Member

Inclusion Criteria:

  1. 40-80 years old, regardless of BP level and antihypertensive treatment;
  2. No travel plan for more than 1 month during the study period;
  3. Written or fingerprinted form.

Exclusion Criteria:

  1. Significant cognitive dysfunction;
  2. With advanced tumor, dialysis, or other serious diseases;
  3. Lying in bed for a long time or unable to take care of themselves;
  4. Diagnosed of secondary hypertension;
  5. Having birth plans in the next six months, pregnant or lactating women;
  6. Other ineligible circumstances judged by the investigators.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8,001 participants (actual)

Study arms

  • Experimental
    Multifaceted intervention

    Residents in this group will receive multifaceted intervention including education for a healthy lifestyle, free provision of sodium substitute, weight management, physical exercise, BP monitoring, and appropriate antihypertensive treatment for individuals with hypertension.

    Behavioral: Multifaceted intervention

  • No intervention
    Usual care

    Residents in this group will receive usual lifestyle and health care management.

Interventions

  • BehavioralMultifaceted intervention

    The multifaceted interventions is comprised of the following components: 1. To establish a BP management team led by family health instructor. The team members also include family leaders and village doctors. 2. To conduct multifaceted intervention, which includes education for a healthy lifestyle, free provision of sodium substitute, weight management, physical exercise, BP monitoring, and appropriate antihypertensive treatment for individuals with hypertension.

06

What researchers measure

Primary outcomes

  1. The changes of systolic blood pressure from baseline to 6 months

    The systolic blood pressure changes from baseline to 6 months for all villagers, reported as the difference between intervention and control group.

    Time frame: 6 months

Secondary outcomes

  1. The changes of systolic blood pressure from baseline to 12 months

    The systolic blood pressure changes from baseline to 12 months, reported as the difference between intervention and control group.

    Time frame: 12 months

  2. The changes of diastolic blood pressure from baseline to 6 months

    The diastolic blood pressure changes from baseline to 6 months, reported as the difference between intervention and control group.

    Time frame: 6 months

  3. The proportion of participants with SBP<130 or DBP<80 mmHg at 6 months

    The proportion of participants with SBP\<130 or DBP\<80 mmHg at 6 months

    Time frame: 6 months

  4. The proportion of participants with antihypertensive therapy at 6 months

    The proportion of participants with antihypertensive therapy at 6 months

    Time frame: 6 months

07

Study locations

1 site
  • Ruyang County People's Hospital
    Luoyang, Henan, China
08

References and documents

Publications

  • Tang Y, Jiang C, Guo J, Li Y, Wang C, Chu SH, Wang Z, Wu Y, Hua C, Lu Y, Zhang S, Song Y, Han R, Dong J, Ma C, Cai J, Anderson CS, Du X. Study protocol for the healthy family program on population blood pressure: A multicenter, parallel group, cluster randomized, controlled trial in rural China. Am Heart J. 2025 May;283:70-80. doi: 10.1016/j.ahj.2025.01.014. Epub 2025 Jan 28. PubMed 39884452 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Feb 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2024
First posted
May 23, 2024
StartActual
May 23, 2024
Primary completionActual
Feb 12, 2025
CompletionActual
Jul 28, 2025
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06427096
Lead sponsor
Heart Health Research Center
Collaborators
National Science and Technology Major Project
Responsible party
Sponsor
First posted
May 23, 2024
Start date
May 23, 2024
Primary completion
Feb 12, 2025
Completion
Jul 28, 2025
Last update
Mar 4, 2026

Study contacts

Jun Cai, MD
principal investigator · Beijing Anzhen Hospital
Xin Du, MD
principal investigator · Beijing Anzhen Hospital
Craig S Anderson, MD
principal investigator · Institute of Science and Technology for Brain-Inspired Intelligence
Chao Jiang, MD
principal investigator · Beijing Anzhen Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion